Eupraxia Appoints Alex Rothwell To Succeed Bruce Cousins As CFO

(RTTNews) - Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, Tuesday announced the appointment of Alex Rothwell as Chief Financial Officer, with effect immediately. Earlier, Rothwell had served as CFO and capital markets consultant of Eupraxia.

Current CFO Bruce Cousins will retire but will stay on as a consultant for a smooth transition.

Rothwell has more than 25 years of experience as a business leader and as a senior executive and has previously worked as CFO of Eupraxia from 2018 to 2021. Rothwell recently has been a Senior Advisor to Fort Capital Partners.

Alex Rothwell said, "...we anticipate that EP-104IAR, for the treatment of pain due to osteoarthritis of the knee, can become a key therapy to treat this large patient population and that its market can be materially expanded by use in other joint areas."

On Monday, Eupraxia had closed 1.54% higher at $3.29 on the Nasdaq.